The efficient FOBT-based screening programmes in the Dutch setting (see also the efficient frontier in figure 2) (MISCAN-Colon predictions)*
| No. | Screening test | Cut-off for referral to colonoscopy (ng/mL)† | Screening interval (years) | Start age (years) | Stop age (years) | Number of screens (n) | Costs (€) | LYs gained (n) | Incremental costs per LY gained (€/LY gained) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FIT | 50 | 3 | 60 | 69 | 4 | 91 000 | 57 | 1600 |
| 2 | FIT | 50 | 3 | 55 | 70 | 6 | 131 000 | 75 | 2200 |
| 3 | FIT | 50 | 3 | 55 | 73 | 7 | 149 000 | 82 | 2800 |
| 4 | FIT | 50 | 2 | 55 | 75 | 11 | 201 000 | 95 | 3900 |
| 5 | FIT | 50 | 1.5 | 55 | 74.5 | 14 | 237 000 | 103 | 4300 |
| 6 | FIT | 50 | 1.5 | 55 | 79 | 17 | 273 000 | 110 | 5300 |
| 7 | FIT | 50 | 2 | 50 | 80 | 16 | 293 000 | 114 | 5800 |
| 8 | FIT | 50 | 1.5 | 50 | 80 | 21 | 344 000 | 119 | 8900 |
| 9 | FIT | 50 | 1.5 | 45 | 79.5 | 24 | 397 000 | 125 | 9400 |
| 10 | FIT | 50 | 1 | 45 | 80 | 36 | 515 000 | 133 | 14 900 |
*Costs and LYs gained per 1000 individuals aged 45–80 in 2005 compared with no screening (3% discounted). Results for all simulated screening programmes are shown in figure 2. This analysis is described in detail in a paper by Wilschut and colleagues.32
†50 ng/mL corresponds with 10 µg/g.
FIT, faecal immunochemical test; FOBT, faecal occult blood test; LY, life-year.